I-Mab in talks about deals, stake sale to build on $3B AbbVie alliance — Bloomberg

A year after I-Mab made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie, the Chinese biotech is reportedly holding early talks with global pharma players about partnerships and potential investment.

The Shanghai-based, Nasdaq-listed company is mulling “clinical and commercial cooperation in China and a potential equity...

Click to view original post